Divyaa Ravishankar - Analyst Profile

Senior Industry Analyst
Frost & Sullivan


Experienced in leveraging analytical and research skills to support corporate strategy, business planning and research development

Educational background in Life Sciences with successful career advancement in life science market research and consulting. 

Custom research experience in healthcare areas such as Clinical diagnostics, lifescience research tools, medical devices and medical imaging, life science and healthcare IT. 

Authored syndicated market research reports, white papers and market insights. - Market research specialties include market mapping, business planning, market entry strategies, feasibility studies, competitive benchmarking. Research design, best practice analysis, spread sheet market sizing and forecasting models, client relationship management.

Lab based experience in HLA (human leukocyte antigen) tissue typing for bone marrow transplants. 

Handling automated liquid handling, PCR, sequencing platforms with sophisticated robotics, immunochoromatography techniques, microbiology techniques, gel electrophoresis.

Areas of expertise

Recent items from Divyaa Ravishankar

Laboratories Seek Alternate Revenue Streams to Combat Reimbursement Pressure
Clinical laboratory services represent one of the highest healthcare expenditures in North America, yet the United States and Canada represent different scenarios in the way clinical services are rendered. The market for clinical lab services in Canada was an estimated $10.33 billion in 2017 whereas in the United States it was an estimated $78.33 billion for the same year. Heavily influenced by the Protecting Access to Medicare Act (PAMA) reimbursement cuts, US laboratories are expanding their revenue streams to collaborate with retail clinics and eCommerce channels to increase their testing footprint. Today’s market is ripe for mergers and acquisitions. The private market is heavily concentrated between two reference laboratories, Quest Diagnostics and LabCorp. This report analyzes the market for clinical laboratory services in North America across 3 main segments: hospital laboratories, physician office laboratories, and specialty/independent laboratories. In Canada, regional public laboratories are also analyzed. Revenue forecasts for the period 2018–2022 have been carefully studied to understand the impact of PAMA and the upcoming reimbursement cuts. The study also includes competitive profiles of top vendors serving the United States and Canada for laboratory testing and gives an in-depth analysis of winning strategies for laboratories to survive in a future that is governed by value-based healthcare. Since the market is ripe for mergers and acquisitions, a detailed M&A analysis for the period 2017–2018 is included. In Canada, lab services as well as any innovation pertaining to the introduction of new tests are heavily dependent on Ministry of Health (MoH) funding. Some provinces are more open than others (e.g., Ontario is more open to innovation and introduction of new tests when compared to Quebec.). Ontario, British Columbia, and Quebec are the major markets within Canada. Although similar in the flow of funds and governance by their respective MoHs, it is important to note there is a huge pricing difference observed for clinical tests in each Canadian province. There are downsides to the clinical lab services market in Canada given that several medically necessary tests remain uninsured and not paid for by the MoH. These are covered through private insurance. Also, a substantial amount of outsourcing occurs for genetic testing (sent to the United States, mostly) because of an inadequate strategy for this type of testing. Other areas covered in this research are challenges and drivers impacting the clinical lab services market in the United States and Canada; new business models and alternate revenue channels; winning strategies for clinical labs to combat reimbursement pressure; actionable growth opportunities for companies; and major lab chains by country. Author: Divyaa Ravishankar
Published: Mar 20 2019 Other
Companies are Vying for a Higher Market Position in the Early Cancer Screening Market
Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence. Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology. It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors. Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within “liquid biopsy as a service model”. Currently, there are no clear guidelines that provide a definitive regulatory/ reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages. Top market trends include: • Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities. • Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement. • Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach. • Companies are pushing the boundaries beyond oncology testing.
Published: Oct 05 2018 Other
A Voice of Customer Study to Compare Trends Between Current and Potential Adopters of Digital Pathology Platforms
A digital pathology end-user research was conducted to identify trends and developments in the field of digital pathology. The survey sought to collect the key information on usage and adoption and compare the perceptions of current and potential adopters of this technology. For the survey, lab managers and pathologists of pathology facilities were invited to participate in an online survey conducted between June 2017 and July 2017. To qualify for survey participation, respondents had to be working in a private or public laboratory, clinical research institution, reference laboratory, academic medical center laboratory, hospital lab, or diagnostic company that employs digital pathology. Respondents had to be constant users or potential users of this technology. Overall 154 responses were analyzed; more than 77% of the respondents were from the US and nearly 12% were from Europe. A large percent of users are currently using digital pathology tools for research, followed by digital pathology for teaching and education. However, for potential users, automated image analysis topped the list of encouraging areas. It was interesting to note that FDA clearance as a factor did not top the charts in the case of future user. One of the key trends the survey reflected was the transition of digital pathology to cloud pathology, Cloud-based delivery of solutions has proven to decrease burden on IT staff, and is known to reduce installation time and to eliminate the need for costly IT infrastructure. These benefits can truly globalize digital pathology and promote telepathology to a large extent, for a field in which sharing and communication are vital. Nevertheless, Cloud is only a means to deliver the product; the solution must scale, supply a growing set of functionalities, operate with a central cloud infrastructure, and most importantly, provide a HIPAA-compliant and securely accessible environment. Another key trend that emerged was the various criteria required by future adopters of digital pathology. Ease of operation and customer support and training surprisingly led in terms of importance (well ahead of price) during vendor selection; this was a similar trend for current users of digital pathology. Despite some similarities in responses between current and future users, there is significant insight that can be garnered with the differences found between these groups.
Published: Sep 25 2017 Other
Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection
Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories. Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes. Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States. The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.
Published: Jul 17 2017 Market Research
Published: May 31 2017 Best Practices
US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation
The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of care testing (POCT) and liquid biopsy continue to attract investment opportunities from private equity and venture capitalists. The new government in the United States aims to provide a retail-like experience for healthcare services. As a result, innovative and clinically vetted direct to consumer (DTC) diagnostic testing services are expected to thrive. Partnerships with non-healthcare (HC) companies are expected to empower core diagnostic companies with artificial intelligence (AI) and big data capabilities are on the rise. Given these market trends, it is important to understand the market dynamics to remain competitive and successful in the IVD market in the United States of America. Research Scope: The key objectives of this growth opportunity study are to track the changes in the IVD market landscape in the United States for 2016-2021. The study aims to identify growth segments and disruptive companies to invest into. Further, the study provides an in-depth revenue and market share analysis of over 8 segments within the IVD landscape: POCT, tissue diagnostics, self-monitoring blood glucose meter (SMBG), hemostasis, hematology, clinical chemistry, microbiology, immunochemistry, and molecular diagnostics. The study highlights industry challenges, growth drivers, restraints, competitive developments, mergers and acquisition, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA), identifies transforming business models, and makes strategic recommendations to understand the dynamics of the US IVD market. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies and transforming business models, as well as strategic recommendations. Key Questions this Study will Answer: 1. What are some of the current issues that concern the US IVD industry? How would these impact the different stakeholders in the healthcare landscape? 2. Which are the major segments of growth and why should you invest in them? 3. How to identify partners outside the conventional IVD realm? 4. How can big data support the growth of the IVD industry? 5. What are some of the newer products to watch in 2017 and beyond? 6. Which companies are categorized as early disruptors in this space? Who are the possible candidates to acquire, invest in, and help grow your business?
Published: May 23 2017 Other
Published: 5 May 2017 Next-generation sequencing and the use of genomics in diagnosis and treatment have generated many headlines in recent years, both for advancements on the research front, as well as in the development of diagnostics and pharmaceutical products that leverage genomics in oncology and other early-adopting fields. The question is...
22 May 2017 Blog post
2016 Global Survey on Clinical Next-generation Sequencing
Next-generation sequencing and the use of genomics in diagnosis and treatment have generated many headlines in recent years, both for advancements on the research front, as well as in the development of diagnostics and pharmaceutical products that leverage genomics in oncology and other early-adopting fields.
Published: May 05 2017 Market Insights
Respondents Show Vivid Interest in Developing Clinical NGS-based Tests for Infectious Disease Testing Applications
The primary goal of this research is to analyze the current and future adoption plans of Next-Generation Sequencing (NGS) for clinical applications. The survey seeks to collect the following key information: • Outsourcing needs and clinical NGS service providers • Current and future interest areas of clinical NGS • Genetic elements of interest • Purchase patterns for instruments and reagents • Predominantly used clinical methods (e.g., chip sequencing, whole exome) • Perspectives of NGS used as complement or replacement for current methods • Platforms used for NGS clinical data interpretation • Predominantly cited instruments for clinical use • Familiarity with clinical NGS service providers • Factors promoting adoption • Factors limiting adoption • Best practices from labs—direct quotes from lab managers Research Methodology Lab managers of clinical labs were invited to participate in an online survey during August–November 2016. To qualify for survey participation, respondents had to be working in a private or public laboratory, clinical research institution, reference laboratory, academic medical center facility, hospital lab, or diagnostic company that employs NGS for clinical use. Respondents had to be constant users of this technology, belong to the scientific community, and be in a position to authorize purchases. Over 184 respondents qualified for the survey including C-level officers, lab managers, directors, physicians, post docs, and principal investigators that had a direct interference with the clinical NGS community. End users were also evaluated for their ability to authorize purchases or make product recommendations. Respondents indicated a wide range of job titles, such as lab directors, scientists, lab managers, clinicians, pathologists, and lab technicians. In total, about 82% of respondents work in the United States. Nevertheless, this study is considered global because the survey was open to respondents from all countries.
Published: Jan 09 2017 Customer Research
Explore Potential Partners and Distribution Channels to Increase Market Position in the Direct-to-Consumer Pathway
The objective of this research is to understand the food intolerance and food allergy testing market in the United States. While allergy testing is common, food intolerance testing is provided by very few manufacturers, mostly as laboratory developed tests (LDTs) in the direct-to-consumer (DTC) pathway. The study includes key profiles of food intolerance testing vendors, DTC portals for allergy and intolerance tests, test volume analysis of intolerance testing, and key allergy tests (using relevant CPT codes). Test revenue/unit price estimates for the market are calculated based on the Part B National Summary Analysis for ALCAT tests, blood-based (IgE) and skin tests. The relevant CPT codes are provided. The study period is 2015 to 2019.
Published: Sep 12 2016 Market Insights
Discover the Perfect Assay Price Point to Remain Competitive
The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therapy monitoring). A selective list of therapeutic areas covered in this research include: autoimmune diseases, cancers (breast, colorectal, prostrate, lung, gastric, cervical, and ovarian), toxicology, cardiology, women’s health (vitamin D, prenatal, pregnancy and hormone), and infectious disease testing (TB, hepatitis A/B/C, cytomegalovirus). The base year used for analysis is 2015.
Published: Sep 12 2016 Market Insights
The current regulatory framework for in vitro diagnostics (IVD) is provided by the Directive 98/79/EC of the European Parliament. The new and stricter regulation framework is expected to start in 2014 and is in accordance with the Global Harmonization Task Force on Medical Devices (now operating as the International Medical Device Regulators Forum)...
17 Jan 2014 Blog post

Divyaa's Tweets

Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..